share_log

Mangoceuticals | 10-Q: Q2 2024 Earnings Report

Mangoceuticals | 10-Q: Q2 2024 Earnings Report

Mangoceuticals | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/15 05:20

Moomoo AI 已提取核心信息

Mangoceuticals reported Q2 2024 revenue of $163,163, up 15.5% year-over-year, driven by increased digital marketing efforts and recurring customer subscriptions. Gross profit was $69,792, down from $87,130 in Q2 2023 due to higher shipping costs and promotional discounts. Cost of revenues increased to $93,371 from $54,107 last year, correlating with higher product sales.Operating expenses totaled $2.24 million, with significant investments in legal fees of $165,368, software development of $239,520, and stock-based compensation of $859,380. Marketing expenses decreased to $229,244 from $797,263 last year as the company optimized its advertising strategy. General and administrative expenses rose to $850,704 from $567,655 in Q2 2023.The company ended the quarter with $490,243 in cash and reported a net loss of $2.39 million compared to $2.28 million in Q2 2023. Management secured additional funding through preferred stock offerings and equity purchase agreements to support operations and growth initiatives. The company also acquired key patents related to infection prevention technologies for $20 million through a combination of preferred stock and cash payments.
Mangoceuticals reported Q2 2024 revenue of $163,163, up 15.5% year-over-year, driven by increased digital marketing efforts and recurring customer subscriptions. Gross profit was $69,792, down from $87,130 in Q2 2023 due to higher shipping costs and promotional discounts. Cost of revenues increased to $93,371 from $54,107 last year, correlating with higher product sales.Operating expenses totaled $2.24 million, with significant investments in legal fees of $165,368, software development of $239,520, and stock-based compensation of $859,380. Marketing expenses decreased to $229,244 from $797,263 last year as the company optimized its advertising strategy. General and administrative expenses rose to $850,704 from $567,655 in Q2 2023.The company ended the quarter with $490,243 in cash and reported a net loss of $2.39 million compared to $2.28 million in Q2 2023. Management secured additional funding through preferred stock offerings and equity purchase agreements to support operations and growth initiatives. The company also acquired key patents related to infection prevention technologies for $20 million through a combination of preferred stock and cash payments.
Mangoceuticals报告2024年第二季度营业收入为163,163美元，同比增长15.5%，这得益于数字营销力度的加强和重复客户订阅的增长。毛利润为69,792美元，较2023年第二季度的87,130美元下降，原因是运输成本和促销折扣上升。营业收入成本增加至93,371美元，较去年54,107美元有所上升，这与产品销售的增加相关。营业费用总计224万，法律费用投资显著，为165,368美元，软件开发为239,520美元，股票基础补偿为859,380美元。随着公司优化广告策略，营销费用从去年的797,263美元降至229,244美元。一般和行政费用从2023年第二季度的567,655美元...展开全部
Mangoceuticals报告2024年第二季度营业收入为163,163美元，同比增长15.5%，这得益于数字营销力度的加强和重复客户订阅的增长。毛利润为69,792美元，较2023年第二季度的87,130美元下降，原因是运输成本和促销折扣上升。营业收入成本增加至93,371美元，较去年54,107美元有所上升，这与产品销售的增加相关。营业费用总计224万，法律费用投资显著，为165,368美元，软件开发为239,520美元，股票基础补偿为859,380美元。随着公司优化广告策略，营销费用从去年的797,263美元降至229,244美元。一般和行政费用从2023年第二季度的567,655美元上升至850,704美元。公司在本季度末现金为490,243美元，报告净亏损为239万，相较于2023年第二季度的228万。管理层通过优先股发行和股权购买协议获得了额外资金，以支持运营和增长计划。公司还通过优先股和现金支付的组合以2,000万收购了与感染预防技术相关的关键专利。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Performant Healthcare
    PHLT
    -- 3.000
    SHL Telemedicine
    SHLT
    -- 1.950
    Simulations Plus
    SLP
    -- 24.290
    Mangoceuticals
    MGRX
    -- 2.380
    Forian
    FORA
    -- 2.000
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点